ES2372420T3 - Derivados de n-hidroxiamida y uso de los mismos. - Google Patents

Info

Publication number

ES2372420T3

ES2372420T3 ES06819550T ES06819550T ES2372420T3 ES 2372420 T3 ES2372420 T3 ES 2372420T3 ES 06819550 T ES06819550 T ES 06819550T ES 06819550 T ES06819550 T ES 06819550T ES 2372420 T3 ES2372420 T3 ES 2372420T3

Authority

ES

Spain

Prior art keywords

alkyl

heteroaryl

alkenyl

chosen

alkynyl

Prior art date

2005-11-24

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical class ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 title claims abstract description 24
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 135
• 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 38
• 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract description 37
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract description 35
• 125000003118 aryl group Chemical group 0.000 claims abstract description 33
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract description 31
• 150000003839 salts Chemical class 0.000 claims abstract description 23
• 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract description 21
• 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 21
• 125000003545 alkoxy group Chemical group 0.000 claims abstract description 12
• 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
• 229910052799 carbon Inorganic materials 0.000 claims abstract description 6
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 6
• 150000001875 compounds Chemical class 0.000 claims description 113
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
• 239000000203 mixture Substances 0.000 claims description 28
• 238000011282 treatment Methods 0.000 claims description 26
• 238000000034 method Methods 0.000 claims description 22
• 206010028980 Neoplasm Diseases 0.000 claims description 20
• 201000011510 cancer Diseases 0.000 claims description 18
• 230000004761 fibrosis Effects 0.000 claims description 18
• 206010016654 Fibrosis Diseases 0.000 claims description 17
• 201000010099 disease Diseases 0.000 claims description 16
• 201000006417 multiple sclerosis Diseases 0.000 claims description 16
• 239000008194 pharmaceutical composition Substances 0.000 claims description 15
• 239000003814 drug Substances 0.000 claims description 13
• 239000003795 chemical substances by application Substances 0.000 claims description 12
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
• 238000002360 preparation method Methods 0.000 claims description 12
• 125000006239 protecting group Chemical group 0.000 claims description 12
• 206010014561 Emphysema Diseases 0.000 claims description 10
• 208000006011 Stroke Diseases 0.000 claims description 10
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
• 208000023504 respiratory system disease Diseases 0.000 claims description 10
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 9
• 206010036595 Premature delivery Diseases 0.000 claims description 9
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 9
• 201000009273 Endometriosis Diseases 0.000 claims description 8
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
• 230000004770 neurodegeneration Effects 0.000 claims description 8
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
• 238000011321 prophylaxis Methods 0.000 claims description 8
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
• 208000006673 asthma Diseases 0.000 claims description 7
• 239000003085 diluting agent Substances 0.000 claims description 7
• 208000027866 inflammatory disease Diseases 0.000 claims description 7
• 208000005069 pulmonary fibrosis Diseases 0.000 claims description 6
• IAPRTSNCZDPMNR-UHFFFAOYSA-N trimethyl-[4-[[2-trimethylsilyl-6,7-bis(trimethylsilyloxy)-3,4-dihydro-1h-isoquinolin-1-yl]methyl]-2-trimethylsilyloxyphenoxy]silane Chemical compound C1=C(O[Si](C)(C)C)C(O[Si](C)(C)C)=CC=C1CC1C2=CC(O[Si](C)(C)C)=C(O[Si](C)(C)C)C=C2CCN1[Si](C)(C)C IAPRTSNCZDPMNR-UHFFFAOYSA-N 0.000 claims description 6
• 208000019693 Lung disease Diseases 0.000 claims description 5
• 230000001684 chronic effect Effects 0.000 claims description 5
• 206010050207 Skin fibrosis Diseases 0.000 claims description 4
• 230000000414 obstructive effect Effects 0.000 claims description 4
• 230000008569 process Effects 0.000 claims description 4
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 claims 2
• ZXKINMCYCKHYFR-UHFFFAOYSA-N aminooxidanide Chemical compound [O-]N ZXKINMCYCKHYFR-UHFFFAOYSA-N 0.000 claims 1
• 230000002440 hepatic effect Effects 0.000 claims 1
• -1 ethylphenyl Chemical group 0.000 description 197
• 102000008186 Collagen Human genes 0.000 description 33
• 108010035532 Collagen Proteins 0.000 description 33
• 229920001436 collagen Polymers 0.000 description 33
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 29
• 102000002274 Matrix Metalloproteinases Human genes 0.000 description 27
• 108010000684 Matrix Metalloproteinases Proteins 0.000 description 27
• 238000004458 analytical method Methods 0.000 description 23
• 241001465754 Metazoa Species 0.000 description 22
• 239000000243 solution Substances 0.000 description 22
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 20
• 230000015572 biosynthetic process Effects 0.000 description 19
• 239000003981 vehicle Substances 0.000 description 18
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 17
• 125000004076 pyridyl group Chemical group 0.000 description 17
• 108010050904 Interferons Proteins 0.000 description 16
• 102000014150 Interferons Human genes 0.000 description 16
• 206010033799 Paralysis Diseases 0.000 description 16
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 16
• 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 15
• 208000035475 disorder Diseases 0.000 description 14
• 239000000758 substrate Substances 0.000 description 14
• 238000012360 testing method Methods 0.000 description 14
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 13
• 102000000588 Interleukin-2 Human genes 0.000 description 13
• 108010002350 Interleukin-2 Proteins 0.000 description 13
• 229940121363 anti-inflammatory agent Drugs 0.000 description 13
• 239000002260 anti-inflammatory agent Substances 0.000 description 13
• 229940079322 interferon Drugs 0.000 description 13
• 239000000047 product Substances 0.000 description 13
• 102100026802 72 kDa type IV collagenase Human genes 0.000 description 12
• 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 12
• SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 12
• 230000000694 effects Effects 0.000 description 12
• 102000004190 Enzymes Human genes 0.000 description 11
• 108090000790 Enzymes Proteins 0.000 description 11
• 108010005716 Interferon beta-1a Proteins 0.000 description 11
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
• 230000002354 daily effect Effects 0.000 description 11
• 238000000132 electrospray ionisation Methods 0.000 description 11
• 229940088598 enzyme Drugs 0.000 description 11
• 125000004447 heteroarylalkenyl group Chemical group 0.000 description 11
• 230000005764 inhibitory process Effects 0.000 description 11
• 210000004185 liver Anatomy 0.000 description 11
• 238000007920 subcutaneous administration Methods 0.000 description 11
• 208000023275 Autoimmune disease Diseases 0.000 description 10
• 241000699670 Mus sp. Species 0.000 description 10
• 210000004027 cell Anatomy 0.000 description 10
• ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 10
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 10
• 235000019439 ethyl acetate Nutrition 0.000 description 10
• 238000004128 high performance liquid chromatography Methods 0.000 description 10
• 239000007924 injection Substances 0.000 description 10
• 238000002347 injection Methods 0.000 description 10
• 239000000126 substance Substances 0.000 description 10
• 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 9
• 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 9
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 9
• 208000019425 cirrhosis of liver Diseases 0.000 description 9
• 239000001257 hydrogen Substances 0.000 description 9
• 239000003112 inhibitor Substances 0.000 description 9
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
• 238000003786 synthesis reaction Methods 0.000 description 9
• 101710151806 72 kDa type IV collagenase Proteins 0.000 description 8
• 108010010803 Gelatin Proteins 0.000 description 8
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
• 239000008273 gelatin Substances 0.000 description 8
• 229920000159 gelatin Polymers 0.000 description 8
• 235000019322 gelatine Nutrition 0.000 description 8
• 235000011852 gelatine desserts Nutrition 0.000 description 8
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 8
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
• 239000002904 solvent Substances 0.000 description 8
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 7
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 7
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
• 230000000172 allergic effect Effects 0.000 description 7
• 208000010668 atopic eczema Diseases 0.000 description 7
• 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 7
• 238000006243 chemical reaction Methods 0.000 description 7
• 238000009472 formulation Methods 0.000 description 7
• 238000007912 intraperitoneal administration Methods 0.000 description 7
• 210000004698 lymphocyte Anatomy 0.000 description 7
• 230000036210 malignancy Effects 0.000 description 7
• 208000030159 metabolic disease Diseases 0.000 description 7
• 108090000765 processed proteins & peptides Proteins 0.000 description 7
• 125000003107 substituted aryl group Chemical group 0.000 description 7
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
• 102000029816 Collagenase Human genes 0.000 description 6
• 108060005980 Collagenase Proteins 0.000 description 6
• 208000016192 Demyelinating disease Diseases 0.000 description 6
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
• 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 6
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
• 239000002253 acid Substances 0.000 description 6
• 125000000217 alkyl group Chemical group 0.000 description 6
• 125000000304 alkynyl group Chemical group 0.000 description 6
• 206010003246 arthritis Diseases 0.000 description 6
• 125000005018 aryl alkenyl group Chemical group 0.000 description 6
• 239000002775 capsule Substances 0.000 description 6
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
• 235000019504 cigarettes Nutrition 0.000 description 6
• 239000012230 colorless oil Substances 0.000 description 6
• 125000000753 cycloalkyl group Chemical group 0.000 description 6
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
• 230000002401 inhibitory effect Effects 0.000 description 6
• NRNMEPJQMFIAOB-QFIPXVFZSA-N n-hydroxy-n-[(2s)-4-methyl-2-[4-(4-phenylphenyl)piperazine-1-carbonyl]pentyl]formamide Chemical compound C1CN(C(=O)[C@H](CN(O)C=O)CC(C)C)CCN1C1=CC=C(C=2C=CC=CC=2)C=C1 NRNMEPJQMFIAOB-QFIPXVFZSA-N 0.000 description 6
• 201000008482 osteoarthritis Diseases 0.000 description 6
• 239000002953 phosphate buffered saline Substances 0.000 description 6
• 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 6
• 125000000714 pyrimidinyl group Chemical group 0.000 description 6
• 125000005415 substituted alkoxy group Chemical group 0.000 description 6
• 125000001544 thienyl group Chemical group 0.000 description 6
• 125000001917 2,4-dinitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1*)[N+]([O-])=O)[N+]([O-])=O 0.000 description 5
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 5
• 102000012422 Collagen Type I Human genes 0.000 description 5
• 108010022452 Collagen Type I Proteins 0.000 description 5
• 108010067306 Fibronectins Proteins 0.000 description 5
• 102000016359 Fibronectins Human genes 0.000 description 5
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
• 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 5
• 125000005037 alkyl phenyl group Chemical group 0.000 description 5
• 125000003710 aryl alkyl group Chemical group 0.000 description 5
• 208000037979 autoimmune inflammatory disease Diseases 0.000 description 5
• 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 5
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 5
• 239000004305 biphenyl Substances 0.000 description 5
• 235000010290 biphenyl Nutrition 0.000 description 5
• YFNONBGXNFCTMM-UHFFFAOYSA-N butoxybenzene Chemical group CCCCOC1=CC=CC=C1 YFNONBGXNFCTMM-UHFFFAOYSA-N 0.000 description 5
• 239000001768 carboxy methyl cellulose Substances 0.000 description 5
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 125000000068 chlorophenyl group Chemical group 0.000 description 5
• 238000004440 column chromatography Methods 0.000 description 5
• 235000001671 coumarin Nutrition 0.000 description 5
• 229960000956 coumarin Drugs 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 238000002474 experimental method Methods 0.000 description 5
• 125000001207 fluorophenyl group Chemical group 0.000 description 5
• 229910052736 halogen Inorganic materials 0.000 description 5
• 150000002367 halogens Chemical class 0.000 description 5
• 150000002431 hydrogen Chemical group 0.000 description 5
• 210000003141 lower extremity Anatomy 0.000 description 5
• 238000004949 mass spectrometry Methods 0.000 description 5
• 239000002609 medium Substances 0.000 description 5
• 125000001715 oxadiazolyl group Chemical group 0.000 description 5
• 230000036961 partial effect Effects 0.000 description 5
• 239000000843 powder Substances 0.000 description 5
• DSNYFFJTZPIKFZ-UHFFFAOYSA-N propoxybenzene Chemical group CCCOC1=CC=CC=C1 DSNYFFJTZPIKFZ-UHFFFAOYSA-N 0.000 description 5
• 125000003373 pyrazinyl group Chemical group 0.000 description 5
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 5
• 229940038850 rebif Drugs 0.000 description 5
• 229910002027 silica gel Inorganic materials 0.000 description 5
• 239000000741 silica gel Substances 0.000 description 5
• 229960001866 silicon dioxide Drugs 0.000 description 5
• 238000010186 staining Methods 0.000 description 5
• ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical compound C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 5
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 5
• 108010021749 7-methoxycoumarin-4-yl-acetyl-prolyl-leucyl-glycyl-leucyl-(3-(2,4-dinitrophenyl)-2,3-diaminopropanoyl)-alanyl-argininamide Proteins 0.000 description 4
• 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
• 108010082126 Alanine transaminase Proteins 0.000 description 4
• 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
• 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
• 201000001320 Atherosclerosis Diseases 0.000 description 4
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 4
• 102100027995 Collagenase 3 Human genes 0.000 description 4
• 206010012305 Demyelination Diseases 0.000 description 4
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
• 239000007821 HATU Substances 0.000 description 4
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
• 206010061218 Inflammation Diseases 0.000 description 4
• 102000005741 Metalloproteases Human genes 0.000 description 4
• 108010006035 Metalloproteases Proteins 0.000 description 4
• YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 4
• 201000004681 Psoriasis Diseases 0.000 description 4
• 125000003342 alkenyl group Chemical group 0.000 description 4
• 239000002585 base Substances 0.000 description 4
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 4
• 229940105329 carboxymethylcellulose Drugs 0.000 description 4
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
• 229960002424 collagenase Drugs 0.000 description 4
• 230000008878 coupling Effects 0.000 description 4
• 238000010168 coupling process Methods 0.000 description 4
• 238000005859 coupling reaction Methods 0.000 description 4
• 125000004802 cyanophenyl group Chemical group 0.000 description 4
• 230000014509 gene expression Effects 0.000 description 4
• 125000005312 heteroarylalkynyl group Chemical group 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• 239000000543 intermediate Substances 0.000 description 4
• 239000007788 liquid Substances 0.000 description 4
• 239000000314 lubricant Substances 0.000 description 4
• 235000019359 magnesium stearate Nutrition 0.000 description 4
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
• 229910052757 nitrogen Inorganic materials 0.000 description 4
• 238000000746 purification Methods 0.000 description 4
• 239000007787 solid Substances 0.000 description 4
• 210000000278 spinal cord Anatomy 0.000 description 4
• 125000001424 substituent group Chemical group 0.000 description 4
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
• 125000001113 thiadiazolyl group Chemical group 0.000 description 4
• 125000003396 thiol group Chemical group [H]S* 0.000 description 4
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
• LVJYPJZCBGWFQB-INIZCTEOSA-N (2s)-4-methyl-2-[[(2-methylpropan-2-yl)oxycarbonyl-phenylmethoxyamino]methyl]pentanoic acid Chemical compound CC(C)C[C@H](C(O)=O)CN(C(=O)OC(C)(C)C)OCC1=CC=CC=C1 LVJYPJZCBGWFQB-INIZCTEOSA-N 0.000 description 3
• 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 3
• BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
• 108050005238 Collagenase 3 Proteins 0.000 description 3
• QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
• 102000016942 Elastin Human genes 0.000 description 3
• 108010014258 Elastin Proteins 0.000 description 3
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
• 102000013382 Gelatinases Human genes 0.000 description 3
• 108010026132 Gelatinases Proteins 0.000 description 3
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
• 108090000467 Interferon-beta Proteins 0.000 description 3
• 102100027998 Macrophage metalloelastase Human genes 0.000 description 3
• 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 3
• 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 3
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
• 101150101095 Mmp12 gene Proteins 0.000 description 3
• 102100030411 Neutrophil collagenase Human genes 0.000 description 3
• 101710118230 Neutrophil collagenase Proteins 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 229920001213 Polysorbate 20 Polymers 0.000 description 3
• 102100030416 Stromelysin-1 Human genes 0.000 description 3
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 229940003504 avonex Drugs 0.000 description 3
• 230000003376 axonal effect Effects 0.000 description 3
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
• 239000011230 binding agent Substances 0.000 description 3
• 230000037396 body weight Effects 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 230000015556 catabolic process Effects 0.000 description 3
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
• 238000010511 deprotection reaction Methods 0.000 description 3
• 238000011161 development Methods 0.000 description 3
• BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 3
• 229920002549 elastin Polymers 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 230000003203 everyday effect Effects 0.000 description 3
• 210000002744 extracellular matrix Anatomy 0.000 description 3
• 230000003176 fibrotic effect Effects 0.000 description 3
• 230000006870 function Effects 0.000 description 3
• 238000010348 incorporation Methods 0.000 description 3
• 229960004461 interferon beta-1a Drugs 0.000 description 3
• 229940047124 interferons Drugs 0.000 description 3
• 230000000670 limiting effect Effects 0.000 description 3
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
• 235000019341 magnesium sulphate Nutrition 0.000 description 3
• 239000000463 material Substances 0.000 description 3
• 108010008217 nidogen Proteins 0.000 description 3
• 125000004433 nitrogen atom Chemical group N* 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 235000019198 oils Nutrition 0.000 description 3
• 238000001543 one-way ANOVA Methods 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 230000037361 pathway Effects 0.000 description 3
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
• 239000002244 precipitate Substances 0.000 description 3
• 208000037803 restenosis Diseases 0.000 description 3
• 239000011780 sodium chloride Substances 0.000 description 3
• 239000007858 starting material Substances 0.000 description 3
• 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 3
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 3
• 239000000725 suspension Substances 0.000 description 3
• 210000001519 tissue Anatomy 0.000 description 3
• OAKBDDKEEOAXNV-UHFFFAOYSA-N 1-(4-phenylphenyl)piperazine Chemical compound C1CNCCN1C1=CC=C(C=2C=CC=CC=2)C=C1 OAKBDDKEEOAXNV-UHFFFAOYSA-N 0.000 description 2
• FTKIARCSSZWRFJ-UHFFFAOYSA-N 2-(2-methylpropyl)propanedioic acid Chemical compound CC(C)CC(C(O)=O)C(O)=O FTKIARCSSZWRFJ-UHFFFAOYSA-N 0.000 description 2
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
• VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 2
• ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical compound [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 2
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
• 206010002329 Aneurysm Diseases 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• 208000026310 Breast neoplasm Diseases 0.000 description 2
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
• 102000004266 Collagen Type IV Human genes 0.000 description 2
• 108010042086 Collagen Type IV Proteins 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
• 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 description 2
• 102000003996 Interferon-beta Human genes 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 102100024130 Matrix metalloproteinase-23 Human genes 0.000 description 2
• 102100026799 Matrix metalloproteinase-28 Human genes 0.000 description 2
• 206010027476 Metastases Diseases 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
• PMDCZENCAXMSOU-UHFFFAOYSA-N N-ethylacetamide Chemical compound CCNC(C)=O PMDCZENCAXMSOU-UHFFFAOYSA-N 0.000 description 2
• 206010061309 Neoplasm progression Diseases 0.000 description 2
• QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
• 108010081690 Pertussis Toxin Proteins 0.000 description 2
• 206010035664 Pneumonia Diseases 0.000 description 2
• 102000016611 Proteoglycans Human genes 0.000 description 2
• 108010067787 Proteoglycans Proteins 0.000 description 2
• 241000700159 Rattus Species 0.000 description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
• 229940124639 Selective inhibitor Drugs 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• 101710108790 Stromelysin-1 Proteins 0.000 description 2
• 229930006000 Sucrose Natural products 0.000 description 2
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 239000012317 TBTU Substances 0.000 description 2
• CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
• RXSUFCOOZSGWSW-UHFFFAOYSA-M acetyloxy-(4-aminophenyl)mercury Chemical compound CC(=O)O[Hg]C1=CC=C(N)C=C1 RXSUFCOOZSGWSW-UHFFFAOYSA-M 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 125000002252 acyl group Chemical group 0.000 description 2
• 125000004442 acylamino group Chemical group 0.000 description 2
• 125000004423 acyloxy group Chemical group 0.000 description 2
• 239000002671 adjuvant Substances 0.000 description 2
• 235000010443 alginic acid Nutrition 0.000 description 2
• 239000000783 alginic acid Substances 0.000 description 2
• 229920000615 alginic acid Polymers 0.000 description 2
• 229960001126 alginic acid Drugs 0.000 description 2
• 150000004781 alginic acids Chemical class 0.000 description 2
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
• 125000005213 alkyl heteroaryl group Chemical group 0.000 description 2
• 150000001412 amines Chemical class 0.000 description 2
• 239000005557 antagonist Substances 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 239000007853 buffer solution Substances 0.000 description 2
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
• 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
• 125000002837 carbocyclic group Chemical group 0.000 description 2
• 210000002808 connective tissue Anatomy 0.000 description 2
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
• 229960003957 dexamethasone Drugs 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 239000002552 dosage form Substances 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
• 238000001704 evaporation Methods 0.000 description 2
• 230000008020 evaporation Effects 0.000 description 2
• 230000003328 fibroblastic effect Effects 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• DYDNPESBYVVLBO-UHFFFAOYSA-N formanilide Chemical compound O=CNC1=CC=CC=C1 DYDNPESBYVVLBO-UHFFFAOYSA-N 0.000 description 2
• 235000019253 formic acid Nutrition 0.000 description 2
• 239000012634 fragment Substances 0.000 description 2
• 125000000524 functional group Chemical group 0.000 description 2
• 125000004404 heteroalkyl group Chemical group 0.000 description 2
• 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 239000004615 ingredient Substances 0.000 description 2
• 238000001990 intravenous administration Methods 0.000 description 2
• 235000015110 jellies Nutrition 0.000 description 2
• 208000019423 liver disease Diseases 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
• 230000000873 masking effect Effects 0.000 description 2
• 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 2
• 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 2
• OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
• 239000008108 microcrystalline cellulose Substances 0.000 description 2
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
• QMIOSTJMAWSILJ-LJAQVGFWSA-N n-[(2s)-4-methyl-2-[4-(4-phenylphenyl)piperazine-1-carbonyl]pentyl]-n-phenylmethoxyformamide Chemical compound C([C@H](CC(C)C)C(=O)N1CCN(CC1)C=1C=CC(=CC=1)C=1C=CC=CC=1)N(C=O)OCC1=CC=CC=C1 QMIOSTJMAWSILJ-LJAQVGFWSA-N 0.000 description 2
• XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 2
• 125000001624 naphthyl group Chemical group 0.000 description 2
• 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 2
• 239000004006 olive oil Substances 0.000 description 2
• 235000008390 olive oil Nutrition 0.000 description 2
• 239000012074 organic phase Substances 0.000 description 2
• 229910052760 oxygen Inorganic materials 0.000 description 2
• MRDGZSKYFPGAKP-UHFFFAOYSA-N para-methoxyphenylpiperazine Chemical compound C1=CC(OC)=CC=C1N1CCNCC1 MRDGZSKYFPGAKP-UHFFFAOYSA-N 0.000 description 2
• 239000012188 paraffin wax Substances 0.000 description 2
• 125000004193 piperazinyl group Chemical group 0.000 description 2
• ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical group C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 2
• 239000013641 positive control Substances 0.000 description 2
• 239000002243 precursor Substances 0.000 description 2
• 230000002265 prevention Effects 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 229940002612 prodrug Drugs 0.000 description 2
• 239000000651 prodrug Substances 0.000 description 2
• 230000002035 prolonged effect Effects 0.000 description 2
• 239000011541 reaction mixture Substances 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 238000000926 separation method Methods 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 229910001220 stainless steel Inorganic materials 0.000 description 2
• 239000010935 stainless steel Substances 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 238000007619 statistical method Methods 0.000 description 2
• 150000003431 steroids Chemical class 0.000 description 2
• 239000011550 stock solution Substances 0.000 description 2
• 108091007196 stromelysin Proteins 0.000 description 2
• 239000005720 sucrose Substances 0.000 description 2
• 229910052717 sulfur Inorganic materials 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 125000001412 tetrahydropyranyl group Chemical group 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
• 230000005751 tumor progression Effects 0.000 description 2
• 210000001364 upper extremity Anatomy 0.000 description 2
• YLOCGHYTXIINAI-XKUOMLDTSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 YLOCGHYTXIINAI-XKUOMLDTSA-N 0.000 description 1
• IORUGNBWOIUSEB-NDEPHWFRSA-N (2s)-4-methyl-2-[(phenylmethoxyamino)methyl]-1-[4-(4-phenylphenyl)piperazin-1-yl]pentan-1-one Chemical compound C([C@H](CC(C)C)C(=O)N1CCN(CC1)C=1C=CC(=CC=1)C=1C=CC=CC=1)NOCC1=CC=CC=C1 IORUGNBWOIUSEB-NDEPHWFRSA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
• 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
• 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
• 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 description 1
• 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
• 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
• 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
• NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
• 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
• PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
• TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
• BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
• ONQBOTKLCMXPOF-UHFFFAOYSA-N 1-ethylpyrrolidine Chemical compound CCN1CCCC1 ONQBOTKLCMXPOF-UHFFFAOYSA-N 0.000 description 1
• IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 1
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
• IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
• 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 1
• NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
• YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
• 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
• 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
• ZGFJFBOLVLFLLN-ZNLRHDTNSA-N 4-(4-chlorophenyl)-1-[(3e)-3-[9-(2-hydroxypropan-2-yl)-5h-[1]benzoxepino[3,4-b]pyridin-11-ylidene]propyl]-3,3-dimethylpiperidin-4-ol Chemical group C12=CC(C(C)(O)C)=CC=C2OCC2=NC=CC=C2\C1=C/CCN(CC1(C)C)CCC1(O)C1=CC=C(Cl)C=C1 ZGFJFBOLVLFLLN-ZNLRHDTNSA-N 0.000 description 1
• NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical group NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 1
• ZTYBXGGJPMAOMK-UHFFFAOYSA-N 4-benzyl-3-[4-methyl-2-[(phenylmethoxyamino)methyl]pentanoyl]-1,3-oxazolidin-2-one Chemical compound C=1C=CC=CC=1CC1COC(=O)N1C(=O)C(CC(C)C)CNOCC1=CC=CC=C1 ZTYBXGGJPMAOMK-UHFFFAOYSA-N 0.000 description 1
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
• 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
• 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 239000004475 Arginine Substances 0.000 description 1
• 206010003210 Arteriosclerosis Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical compound C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 description 1
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
• 208000031229 Cardiomyopathies Diseases 0.000 description 1
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical class [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
• 229920002261 Corn starch Polymers 0.000 description 1
• 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
• 206010013774 Dry eye Diseases 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 241000588724 Escherichia coli Species 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 239000001263 FEMA 3042 Substances 0.000 description 1
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
• 108010072051 Glatiramer Acetate Proteins 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000627872 Homo sapiens 72 kDa type IV collagenase Proteins 0.000 description 1
• 101001011906 Homo sapiens Matrix metalloproteinase-14 Proteins 0.000 description 1
• 101000627851 Homo sapiens Matrix metalloproteinase-23 Proteins 0.000 description 1
• 101000627852 Homo sapiens Matrix metalloproteinase-25 Proteins 0.000 description 1
• 101000627854 Homo sapiens Matrix metalloproteinase-26 Proteins 0.000 description 1
• 101000627861 Homo sapiens Matrix metalloproteinase-28 Proteins 0.000 description 1
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 206010020649 Hyperkeratosis Diseases 0.000 description 1
• 206010020772 Hypertension Diseases 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010021639 Incontinence Diseases 0.000 description 1
• 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
• 102100026720 Interferon beta Human genes 0.000 description 1
• 108010005714 Interferon beta-1b Proteins 0.000 description 1
• 208000012659 Joint disease Diseases 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical class CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 108700010340 Leishmanolysins Proteins 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 101150014058 MMP1 gene Proteins 0.000 description 1
• 108030001712 Macrophage elastases Proteins 0.000 description 1
• 206010025421 Macule Diseases 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 239000004425 Makrolon Substances 0.000 description 1
• 102100030417 Matrilysin Human genes 0.000 description 1
• 108090000855 Matrilysin Proteins 0.000 description 1
• 108010076503 Matrix Metalloproteinase 13 Proteins 0.000 description 1
• 108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
• 102100030200 Matrix metalloproteinase-16 Human genes 0.000 description 1
• 108090000561 Matrix metalloproteinase-16 Proteins 0.000 description 1
• 102100030219 Matrix metalloproteinase-17 Human genes 0.000 description 1
• 108090000585 Matrix metalloproteinase-17 Proteins 0.000 description 1
• 108090000587 Matrix metalloproteinase-19 Proteins 0.000 description 1
• 102000004055 Matrix metalloproteinase-19 Human genes 0.000 description 1
• 108050006284 Matrix metalloproteinase-23 Proteins 0.000 description 1
• 102100024129 Matrix metalloproteinase-24 Human genes 0.000 description 1
• 108050005214 Matrix metalloproteinase-24 Proteins 0.000 description 1
• 102100024131 Matrix metalloproteinase-25 Human genes 0.000 description 1
• 102100024128 Matrix metalloproteinase-26 Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 244000246386 Mentha pulegium Species 0.000 description 1
• 235000016257 Mentha pulegium Nutrition 0.000 description 1
• 235000004357 Mentha x piperita Nutrition 0.000 description 1
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
• 102000036436 Metzincins Human genes 0.000 description 1
• 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
• NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
• 238000005481 NMR spectroscopy Methods 0.000 description 1
• 208000012902 Nervous system disease Diseases 0.000 description 1
• 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
• 208000025966 Neurological disease Diseases 0.000 description 1
• 102000056189 Neutrophil collagenases Human genes 0.000 description 1
• 108030001564 Neutrophil collagenases Proteins 0.000 description 1
• 244000061176 Nicotiana tabacum Species 0.000 description 1
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 239000006057 Non-nutritive feed additive Substances 0.000 description 1
• 239000004677 Nylon Substances 0.000 description 1
• 208000011623 Obstructive Lung disease Diseases 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 102000016387 Pancreatic elastase Human genes 0.000 description 1
• 108010067372 Pancreatic elastase Proteins 0.000 description 1
• 206010033645 Pancreatitis Diseases 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 229920002230 Pectic acid Polymers 0.000 description 1
• LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical class OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
• 108010020346 Polyglutamic Acid Proteins 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
• 208000032056 Radiation Fibrosis Syndrome Diseases 0.000 description 1
• 206010067953 Radiation fibrosis Diseases 0.000 description 1
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
• 208000014151 Stomatognathic disease Diseases 0.000 description 1
• 102100028848 Stromelysin-2 Human genes 0.000 description 1
• 101710108792 Stromelysin-2 Proteins 0.000 description 1
• 102100028847 Stromelysin-3 Human genes 0.000 description 1
• 108050005271 Stromelysin-3 Proteins 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical class [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 201000009594 Systemic Scleroderma Diseases 0.000 description 1
• 206010042953 Systemic sclerosis Diseases 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 208000000491 Tendinopathy Diseases 0.000 description 1
• 206010043255 Tendonitis Diseases 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 239000013504 Triton X-100 Substances 0.000 description 1
• 229920004890 Triton X-100 Polymers 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• 206010064996 Ulcerative keratitis Diseases 0.000 description 1
• 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
• 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
• 241000700605 Viruses Species 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 229940022663 acetate Drugs 0.000 description 1
• 235000011054 acetic acid Nutrition 0.000 description 1
• 229960000583 acetic acid Drugs 0.000 description 1
• ORWKVZNEPHTCQE-UHFFFAOYSA-N acetic formic anhydride Chemical compound CC(=O)OC=O ORWKVZNEPHTCQE-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000011149 active material Substances 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 206010069351 acute lung injury Diseases 0.000 description 1
• 206010001053 acute respiratory failure Diseases 0.000 description 1
• 239000002487 adenosine deaminase inhibitor Substances 0.000 description 1
• 230000001476 alcoholic effect Effects 0.000 description 1
• 229910052783 alkali metal Inorganic materials 0.000 description 1
• 150000001340 alkali metals Chemical class 0.000 description 1
• 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
• 150000001342 alkaline earth metals Chemical class 0.000 description 1
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
• 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
• 125000005036 alkoxyphenyl group Chemical group 0.000 description 1
• 150000003973 alkyl amines Chemical class 0.000 description 1
• 125000002877 alkyl aryl group Chemical group 0.000 description 1
• 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
• 239000013566 allergen Substances 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 229940024606 amino acid Drugs 0.000 description 1
• 235000001014 amino acid Nutrition 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 238000000540 analysis of variance Methods 0.000 description 1
• 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
• 230000000118 anti-neoplastic effect Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 239000002246 antineoplastic agent Substances 0.000 description 1
• 229940041181 antineoplastic drug Drugs 0.000 description 1
• 208000007474 aortic aneurysm Diseases 0.000 description 1
• 239000012736 aqueous medium Substances 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
• 208000011775 arteriosclerosis disease Diseases 0.000 description 1
• 230000001174 ascending effect Effects 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• 239000012911 assay medium Substances 0.000 description 1
• 238000011914 asymmetric synthesis Methods 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
• 229960002170 azathioprine Drugs 0.000 description 1
• 210000002469 basement membrane Anatomy 0.000 description 1
• JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 229960004365 benzoic acid Drugs 0.000 description 1
• IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical class C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• SVXPPSFKJQWISH-UHFFFAOYSA-N benzyl carbamoperoxoate Chemical compound NC(=O)OOCC1=CC=CC=C1 SVXPPSFKJQWISH-UHFFFAOYSA-N 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• 125000002619 bicyclic group Chemical group 0.000 description 1
• 230000002146 bilateral effect Effects 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 239000013060 biological fluid Substances 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 201000008275 breast carcinoma Diseases 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• 229910052794 bromium Inorganic materials 0.000 description 1
• 239000007975 buffered saline Substances 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229910052791 calcium Inorganic materials 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 235000011148 calcium chloride Nutrition 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 230000012292 cell migration Effects 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 239000007810 chemical reaction solvent Substances 0.000 description 1
• 238000004296 chiral HPLC Methods 0.000 description 1
• 239000000460 chlorine Substances 0.000 description 1
• 229910052801 chlorine Inorganic materials 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• 108700004333 collagenase 1 Proteins 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 239000008120 corn starch Substances 0.000 description 1
• 238000012937 correction Methods 0.000 description 1
• IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
• 229960000258 corticotropin Drugs 0.000 description 1
• 239000007822 coupling agent Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 238000011157 data evaluation Methods 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 238000001514 detection method Methods 0.000 description 1
• 238000010918 diastereoselective addition Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
• 230000009266 disease activity Effects 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 238000009513 drug distribution Methods 0.000 description 1
• 201000002491 encephalomyelitis Diseases 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
• 210000003979 eosinophil Anatomy 0.000 description 1
• QCYAXXZCQKMTMO-QFIPXVFZSA-N ethyl (2s)-2-[(2-bromo-3-oxospiro[3.5]non-1-en-1-yl)amino]-3-[4-(2,7-naphthyridin-1-ylamino)phenyl]propanoate Chemical group N([C@@H](CC=1C=CC(NC=2C3=CN=CC=C3C=CN=2)=CC=1)C(=O)OCC)C1=C(Br)C(=O)C11CCCCC1 QCYAXXZCQKMTMO-QFIPXVFZSA-N 0.000 description 1
• 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000005284 excitation Effects 0.000 description 1
• 238000013401 experimental design Methods 0.000 description 1
• 238000013265 extended release Methods 0.000 description 1
• 229960004979 fampridine Drugs 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• 238000001914 filtration Methods 0.000 description 1
• 229960000556 fingolimod Drugs 0.000 description 1
• KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 229910052731 fluorine Inorganic materials 0.000 description 1
• 239000011737 fluorine Substances 0.000 description 1
• 239000006260 foam Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 235000013355 food flavoring agent Nutrition 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 230000022244 formylation Effects 0.000 description 1
• 238000006170 formylation reaction Methods 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 229940050411 fumarate Drugs 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 235000011087 fumaric acid Nutrition 0.000 description 1
• 229960002598 fumaric acid Drugs 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 208000007565 gingivitis Diseases 0.000 description 1
• 229940042385 glatiramer Drugs 0.000 description 1
• 206010061989 glomerulosclerosis Diseases 0.000 description 1
• 229940050410 gluconate Drugs 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 125000005059 halophenyl group Chemical group 0.000 description 1
• 230000035876 healing Effects 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 206010019692 hepatic necrosis Diseases 0.000 description 1
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000005241 heteroarylamino group Chemical group 0.000 description 1
• 208000010726 hind limb paralysis Diseases 0.000 description 1
• 235000001050 hortel pimenta Nutrition 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical class OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
• 150000002443 hydroxylamines Chemical class 0.000 description 1
• 125000005946 imidazo[1,2-a]pyridyl group Chemical group 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 230000028709 inflammatory response Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• 150000007529 inorganic bases Chemical class 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 1
• 210000000936 intestine Anatomy 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 239000007928 intraperitoneal injection Substances 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• 239000003456 ion exchange resin Substances 0.000 description 1
• 229920003303 ion-exchange polymer Polymers 0.000 description 1
• 125000005990 isobenzothienyl group Chemical group 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 125000005956 isoquinolyl group Chemical group 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 229940001447 lactate Drugs 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• 229960004577 laquinimod Drugs 0.000 description 1
• GKWPCEFFIHSJOE-UHFFFAOYSA-N laquinimod Chemical group OC=1C2=C(Cl)C=CC=C2N(C)C(=O)C=1C(=O)N(CC)C1=CC=CC=C1 GKWPCEFFIHSJOE-UHFFFAOYSA-N 0.000 description 1
• 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 210000005240 left ventricle Anatomy 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 239000003446 ligand Substances 0.000 description 1
• 238000004811 liquid chromatography Methods 0.000 description 1
• 239000006193 liquid solution Substances 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 231100000149 liver necrosis Toxicity 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 239000011976 maleic acid Substances 0.000 description 1
• 229940098895 maleic acid Drugs 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 229940099690 malic acid Drugs 0.000 description 1
• 230000003211 malignant effect Effects 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 108090000440 matrix metalloproteinase 25 Proteins 0.000 description 1
• 230000001404 mediated effect Effects 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 230000009401 metastasis Effects 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
• 229940012189 methyl orange Drugs 0.000 description 1
• 229960001047 methyl salicylate Drugs 0.000 description 1
• 229960004584 methylprednisolone Drugs 0.000 description 1
• 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 229960001156 mitoxantrone Drugs 0.000 description 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
• 230000003562 morphometric effect Effects 0.000 description 1
• 238000013425 morphometry Methods 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• AJFDBNQQDYLMJN-UHFFFAOYSA-N n,n-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 description 1
• APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 description 1
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
• RBVVDFCZCDIJFI-INIZCTEOSA-N n-hydroxy-n-[(2s)-2-[4-(4-methoxyphenyl)piperazine-1-carbonyl]-4-methylpentyl]formamide Chemical compound C1=CC(OC)=CC=C1N1CCN(C(=O)[C@@H](CC(C)C)CN(O)C=O)CC1 RBVVDFCZCDIJFI-INIZCTEOSA-N 0.000 description 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
• PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
• 229960005027 natalizumab Drugs 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 230000003959 neuroinflammation Effects 0.000 description 1
• 230000003448 neutrophilic effect Effects 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 239000002687 nonaqueous vehicle Substances 0.000 description 1
• 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229920001778 nylon Polymers 0.000 description 1
• 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 238000005457 optimization Methods 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 150000007530 organic bases Chemical class 0.000 description 1
• 150000002894 organic compounds Chemical class 0.000 description 1
• 229940116315 oxalic acid Drugs 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
• WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 201000010198 papillary carcinoma Diseases 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 210000004197 pelvis Anatomy 0.000 description 1
• 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
• 208000028169 periodontal disease Diseases 0.000 description 1
• 230000003239 periodontal effect Effects 0.000 description 1
• 201000001245 periodontitis Diseases 0.000 description 1
• 210000003200 peritoneal cavity Anatomy 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• 239000010452 phosphate Chemical class 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical class [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 229960003073 pirfenidone Drugs 0.000 description 1
• 230000036470 plasma concentration Effects 0.000 description 1
• 239000004033 plastic Substances 0.000 description 1
• 229920003023 plastic Polymers 0.000 description 1
• 229920000515 polycarbonate Polymers 0.000 description 1
• 239000010318 polygalacturonic acid Substances 0.000 description 1
• 229920002643 polyglutamic acid Polymers 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 230000008092 positive effect Effects 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 230000017854 proteolysis Effects 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 238000011002 quantification Methods 0.000 description 1
• 238000004445 quantitative analysis Methods 0.000 description 1
• 125000005493 quinolyl group Chemical group 0.000 description 1
• 239000012429 reaction media Substances 0.000 description 1
• 230000035484 reaction time Effects 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 201000004193 respiratory failure Diseases 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229940081974 saccharin Drugs 0.000 description 1
• 235000019204 saccharin Nutrition 0.000 description 1
• 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 239000012047 saturated solution Substances 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 238000007086 side reaction Methods 0.000 description 1
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
• 229960002855 simvastatin Drugs 0.000 description 1
• 239000000779 smoke Substances 0.000 description 1
• 230000000391 smoking effect Effects 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
• 235000010265 sodium sulphite Nutrition 0.000 description 1
• 239000008247 solid mixture Substances 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 238000013222 sprague-dawley male rat Methods 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 239000007929 subcutaneous injection Substances 0.000 description 1
• 238000010254 subcutaneous injection Methods 0.000 description 1
• 229940086735 succinate Drugs 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical class [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 208000024891 symptom Diseases 0.000 description 1
• 238000001308 synthesis method Methods 0.000 description 1
• 235000015523 tannic acid Nutrition 0.000 description 1
• 229940033123 tannic acid Drugs 0.000 description 1
• 229920002258 tannic acid Polymers 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 229960001367 tartaric acid Drugs 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 201000004415 tendinitis Diseases 0.000 description 1
• 229960000331 teriflunomide Drugs 0.000 description 1
• UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 description 1
• 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 238000004809 thin layer chromatography Methods 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 125000003944 tolyl group Chemical group 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
• 125000004953 trihalomethyl group Chemical group 0.000 description 1
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 231100000397 ulcer Toxicity 0.000 description 1
• 125000000297 undecanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000006439 vascular pathology Effects 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 230000029663 wound healing Effects 0.000 description 1
• 239000000230 xanthan gum Substances 0.000 description 1
• 229920001285 xanthan gum Polymers 0.000 description 1
• 235000010493 xanthan gum Nutrition 0.000 description 1
• 229940082509 xanthan gum Drugs 0.000 description 1
• 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1